1 / 39

DEMENTIA the SILENT EPIDEMIC

DEMENTIA the SILENT EPIDEMIC. Antonio A. Graham DO Assistant Professor of Medicine and Geriatrics Emory University School of Medicine. GOMA October 2019. Objectives. Knowledge of incidents and prevalence of patients with dementia in the US population

ollie
Download Presentation

DEMENTIA the SILENT EPIDEMIC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DEMENTIA the SILENT EPIDEMIC Antonio A. Graham DO Assistant Professor of Medicine and Geriatrics Emory University School of Medicine GOMA October 2019

  2. Objectives • Knowledge of incidents and prevalence of patients with dementia in the US population • Recognize signs and symptoms to diagnose dementia • Identify pharmacologic & non-pharmacologic treatment of dementia

  3. DEMENTIA

  4. Why learn about dementia? • 1 in 3 seniors dies with Alzheimer’s or another dementia • Alzheimer’s disease is the 6th leading cause of death in the U.S. • In 2015, Alzheimer’s and other dementias have cost the nation $226 billion+ in health care cost • By 2050, cost could rise as high as $1.1 trillion

  5. Dementia • Dementia is a disorder characterized by problems with cognition + functional impairment • Cognition components: learning/recall, reasoning, language, spatial ability/orientation, and executive function/handling complex tasks • Functional impairments: • Activities of Daily Living (ADLs): eating, dressing, toileting, etc • Instrumental Activities of Daily Living (IADLs): grocery shopping, cooking, finances, medications, driving, etc.

  6. SIGNS of dementia

  7. Dementia subtypes • Alzheimer's disease being the most common subtype (prevalence 50%) • Prominent memory impairment • Gradual decline • Vascular Dementia is the second most common subtype • Tends to have white matter changes on brain imaging & history of strokes or CAD • “Step wise” decline over time

  8. Dementia subtypes • Lewy Body Dementia (prevalence ~15%) • Cognitive impairment, hallucinations, & Parkinson-like symptoms such as shuffling gait, falls, rigidity & tremors • Cognitive & hallucinations may occur before or at the same timeas Parkinson-like symptoms. Parkinson’s Dementia • Must have motor symptoms before cognitive impairment by 1 year

  9. Dementia subtypes • Fronto-temporal Dementia • Usually younger patients, with executive and language dysfunction and often behavioral changes such as disinhibition & impulsivity • Memory impairment less prominent. • Other dementia: 5% • Head trauma, HIV disease, Huntington's chorea, Pick's disease (a type of fronto-temporal dementia), Creutzfeldt-Jakob disease. • Rule out reversible causes: • B12 deficiency, hypothyroidism, neurosyphilis, substance abuse such as alcohol, depression, and delirium

  10. Dementia Screening • Mini Mental Status Exam: measures global cognitive function by examining memory/recall, language, orientation, and executive function. Interpretation of scores depend on level of education (eg. 26/30 would be abnormal in someone with a PhD). MOCA (Montreal Cognitive Assessment) may be used in someone with higher education status. 25-30=normal or mild cognitive impairment 20-24 = dementia, mild 10-20 = dementia, moderate <10 = dementia, severe

  11. Mini-Cog dementia screen • Ask your patient to: • Repeat three words: banana, sunrise, chair • Draw the face of a clock, then draw hands to read “ten past eleven” • Recall the three words

  12. PRIMARY GOAL OF TREATMENTMENT • To enhance quality of life and • maximize functional performance by • improving or stabilizing cognition, mood, and behavior.

  13. NONPHARMACOLOGIC MANAGEMENT (1 of 2) • Cognitive rehabilitation • Supportive individual and group therapy • Physical and mental activity • Regular appointments every 3–6 months • Family and caregiver education and support • Attention to safety • Need for supervision, wandering, driving etc.

  14. NONPHARMACOLOGIC MANAGEMENT (2 of 2) • Environmental modification • Supportive strategies such as clocks, calendars, to-do list, visual clues, simple and compassionate communication style • Structure activities to match patient abilities

  15. PHARMACOLOGIC MANAGEMENT • Treatment should be individualized • Cholinesterase inhibitors: donepezil, rivastigmine, galantamine • Memantine • Other cognitive enhancers • Antidepressants • Psychoactive medications

  16. CHOLINESTERASE INHIBITORS (1 of 2) • Slow breakdown of acetylcholine • Clinical trials demonstrate modest delay in cognitive decline compared with placebo in AD • GI side effects common • Mitigated by slow titration curve • Maximum dosing of donepezil 23 mg/day creates significant side effects without evidence of improving global function

  17. CHOLINESTERASE INHIBITORS (2 of 2) • No evidence of difference in efficacy among drugs • Use in other dementias • Widespread use in vascular dementia not recommended • Attention and behavioral disturbances in Lewy body dementiacan benefit from treatment • Rivastigmine is FDA-approved for mild to moderate dementia in Parkinson dementia • Treatment in fronto-temporal dementia may worsen agitation

  18. MEMANTINE • Neuroprotective effect is to reduce glutamate-mediated excitotoxicity • Modest benefit on cognition, ADLs, and behavior in AD • Limited effect on cognition and no evidence to support widespread use in vascular dementia • FDA-approved for moderate to severe AD • Common adverse events: constipation, dizziness, headache

  19. OTHER COGNITIVE ENHANCERS • Vitamin E (α–tocopherol) may lower rate of functional decline, but no evidence of cognitive improvement in AD • The clinical efficacy and safety of vitamin E has yet to be fully established • Selegilinemay lower rate of functional decline, but no evidence of cognitive improvement in AD • Ginkgo biloba offers no benefit in slowing cognitive decline in MCI

  20. SYMPTOM MANAGEMENT (1 of 2) • Psychoactive medications • Behavioral disturbances best managed nonpharmacologically, eg, reducing overstimulation, environmental modification • When meds are required, target symptoms should be identified, and therapy selected accordingly • Antidepressants • Depressed mood, low appetite, insomnia, fatigue, irritability, agitation • Possibly effective for disinhibition and compulsive behaviors associated with frontotemporal dementia • Caution: falls and anticholinergic effects that may worsen confusion (ie, paroxetine)

  21. SYMPTOM MANAGEMENT (2 of 2) • 1st/2nd-generation antipsychotics • Limited evidence of efficacy and increased risk of all-cause mortality in dementia • Should be used with caution in targeting delusions, hallucinations, paranoia, and irritability ― frequently attempt to taper off • Valproic acid and carbamazepine • Possible options, but with limited evidence and increased risk of mortality • Benzodiazepinesandanticholinergic medications shouldbe avoided

  22. RESOURCES FOR MANAGING DEMENTIA (1 of 2) • Specialist referral to: • Geriatric psychiatrist • Neurologist • Neuropsychologist • Social worker • Physical therapist • Nurse • Pharmacist

  23. RESOURCES FOR MANAGING DEMENTIA (2 of 2) • Attorney: will, conservatorship, estate planning • Community: neighbors & friends, aging & mental health networks, adult day care, respite care, home-health agency • Organizations: Alzheimer’s Association, Area Agencies on Aging, Councils on Aging • Services: Meals-on-Wheels, senior citizen centers

  24. CHOOSING WISELY • Don’t prescribe cholinesterase inhibitors for dementia without periodic assessment for perceived cognitive benefits and adverse gastrointestinal effects. • Don’t use antipsychotics as first choice to treat behavioral and psychological symptoms of dementia.

  25. SUMMARY(1 of 2) • Dementia is common in older adults but is not an inherent part of aging • AD is the most common type of dementia, followed by vascular dementia and dementia with Lewy bodies • Evaluation includes history with informant, physical & functional assessment, focused labs, & possibly brain imaging

  26. SUMMARY(2 of 2) • Primary treatment goals: enhance quality of life and maximize function by improving cognition, mood, behavior • Treatment may involve both medications and nonpharmacologic interventions • Community resources should be used to support patient, family, caregivers

  27. CASE STUDIES

  28. CASE #1 - Scenario • A 65-year-old man comes to the office with his wife because she is concerned about his memory. He is a retired engineer. • His wife offers examples of recent uncharacteristic mistakes that he has made in their finances. • He forgot to pay the mortgage several months ago. • In the grocery store, his credit card was denied for missed payments. • The patient describes his experience. • Balancing accounts feels more effortful & takes longer than it had in the past. • He feels overwhelmed by distractions. • He is frequently unable to find keys and other objects. • He is often unable to recall names of acquaintances until minutes or hours later.

  29. CASE #1 - QUESTION Which one of the following is most likely to indicate pathologic neurologic decline? Taking longer to complete routine tasks Forgetting to pay mortgage and credit card bills Having a complaint about memory Experiencing difficulty retrieving names

  30. CASE #1 - ANSWER Which one of the following is most likely to indicate pathologic neurologic decline? Taking longer to complete routine tasks Forgetting to pay mortgage and credit card bills Having a complaint about memory Experiencing difficulty retrieving names

  31. CASE #2 - Scenario • A 73-year-old man has memory problems that are increasingly evident to his wife, and he has had several unexplained falls. • Neuropsychiatric history: seven years ago he began to have impaired smell, altered taste, and fitful sleep with recurrent dream enactment. • Symptoms have progressed and The dream enactments wake his wife at night. • Fluctuating cognitive dysfunction and bilateral arm tremors developed.

  32. CASE #2 – SCENARIOcont’d • For several years, he has had hallucinations of children in the room. The hallucinations do not frighten him. • The hallucinations worsened when he was hospitalized for a UTI last year. • Neuroleptic agents were administered, but his condition deteriorated and he required restraints for several hours. • Behavioral interventions have been unsuccessful. • History: hypertension, hyperlipidemia, diabetes, urinary incontinence, constipation • MRI of the brain shows mild white matter changes.

  33. CASE #2 - QUESTION Which one of the following medications should NOT be considered for this patient? Clonazepam Donepezil Fludrocortisone Haloperidol Rivastigmine

  34. CASE #2 - ANSWER Which one of the following medications should NOT be considered for this patient? Clonazepam Donepezil Fludrocortisone Haloperidol Rivastigmine

  35. CASE #3 - Question Which one of the following is true regarding the risk of prescribing psychotropic medications to patients with dementia? First- and second-generation antipsychotics increase both morbidity and all cause mortality. Second-generation antipsychotics do not increase morbidity and all cause mortality. First-generation antipsychotics do not increase morbidity and all cause mortality First- and second-generation antipsychotics increase morbidity but not all cause mortality.

  36. CASE #3 - answer Which one of the following is true regarding the risk of prescribing psychotropic medications to patients with dementia? First- and second-generation antipsychotics increase both morbidity and all cause mortality. Second-generation antipsychotics do not increase morbidity and all cause mortality. First-generation antipsychotics do not increase morbidity and all cause mortality First- and second-generation antipsychotics increase morbidity but not all cause mortality.

  37. SUMMARY • Awareness of incidents and prevalence of patients with dementia in the US population • Recognition of signs and symptoms to diagnose dementia • Identification of pharmacologic & non-pharmacologic treatments of dementia • Case studies to test knowledge

  38. For more info: • Alzheimer’s Association: www.alz.org • MOCA (Montreal Cognitive Assessment): www.mocatest.org • Mini-Cog: http://geriatrics.uthscsa.edu/tools/MINICog.pdf • 4AT test: http://www.the4at.com/ • CAM (Confusion Assessment Method): http://www.hospitalelderlifeprogram.org/delirium-instruments/short-cam/

  39. LET’s CONNECT! DR. ANTONIO A. GRAHAM info@drantonioagraham.com @geriagingexpert www.drantonioagraham.com Geriatrician  Educator  Community Health Advocate

More Related